The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Sacubitril/valsartan in primary care: the pharmacist’s role

Sacubitril/valsartan in primary care: the pharmacist’s role

Publication date: Friday, 21 October 2016
Contributor(s): Paul Wright, Sotiris Antoniou

Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.

Sponsorship information:
This sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Paul Wright, Sotiris Antoniou

Article search and filter